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Atrial natriuretic peptide (CDD/ANP-99-126) is rapidly inactivated by a membrane preparation from dog kidney cortex. 
Inactivation occurs by cleavage of the ring structure in the position between Cys-IO5 and Phe-106. A unique proteolytic 
product separated by HPLC on reverse-phase column appears as a single peak which elutes prior the intact peptide. In 
contrast, CDD/ANP-95-126 (urodilatin) which is released from the kidney is not destroyed by proteolysis using an identi- 
cal membrane preparation. 
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1. INTRODUCTION 
In the atria1 specific granules [1] of mammalian 
heart cardiodilatin/atrial natriuretic peptide 
(CDD/ANP) which was first functionally 
characterized by its diuretic activity [2] is stored as 
a prohormone of 126 amino acids in atria1 myo- 
endocrine cells [3-51. In the blood plasma a cir- 
culating bioactive form of CDD/ANP-l-126 
containing 28 residues of the C-terminus of the 
prohormone has been characterized [6,7]. This cir- 
culating peptide exhibits potent natriuretic, 
diuretic and vasorelaxant potency in vitro and in 
vivo [2,5,8-121. Beside CDD/ANP-99-126, a 
variety of shorter forms have been isolated (re- 
views [3,13]). However, it is likely that these 
smaller peptides may be simply the result of hydro- 
lytic artifacts during the purification procedure 
[3,13]. Upon cleavage of the prohormone at a 
single arginine peptide bond, the biologically ac- 
tive form is liberated and circulates as a single pep- 
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tide chain with a disulfide loop formed by two 
cysteine residues [3]. The peptide exhibits a short 
half-life of 3-4 min [ 111. Inactivation of the bioac- 
tive 28-residue peptide in the blood was reported to 
occur (i) by proteolysis of the loop between 
Cys-105 and Phe-106 [6] and (ii) by CAMP- 
dependent phosphorylation of a serine residue in 
position 104, originally described by Rittenhouse 
et al. [14]. The phosphorylation prevents receptor 
binding thus decreasing the vasorelaxant potency 
[15,16]. The humoral role of the heart peptide in 
electrolyte and body fluid volume homeostasis is 
indicated by the presence of high-affinity receptors 
for CDD/ANP in the kidney [ 17,181. Studies im- 
plicate that the kidney is an important site for the 
clearance and subsequent degradation of 
CDD/ANP [ 191. Olins et al. [20] and later Koehn 
et al. [21] reported that kidney cortex membranes 
contain CDD/ANP degrading activity. The 
authors found that inactivation of CDD/ANP oc- 
curs by a single cleavage in the disulfide loop 
region of Cys-105 and Phe-106. 
Cardiac hormones are known to occur also in 
other organs as revealed by mRNA hybridisation 
[22], polypeptide extraction [23] and immuno- 
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logical studies [24-261. By use of the same isolation 
procedure as described for the isolation of the cir- 
culating form of CDD/ANP from human blood 
[7] a peptide of 32 amino acids was isolated from 
urine [27]. Amino acid sequence analysis revealed 
that the CDD/ANP peptide in the urine is a 
32-amino-acid-residue containing molecule (CDD/ 
ANP-95-126). The molecule is N-terminally ex- 
tended compared to CDD/ANP-99-126. It may be 
concluded that the urine peptide is produced and 
processed in the kidney tubules. The urine peptide 
exhibits vasorelaxant potency [28] and was called 
urodilatin [27]. 
A recent finding by our group [29] obtained 
from in vitro perfusion of rabbit kidneys with 
CDD-99-126/a-hANP and urodilatin shows that 
urine outflow was enhanced with urodilatin. 
Therefore, in an effort to elucidate the fate of 
urodilatin interaction with the kidney we have in- 
vestigated the metabolism of CDD-99-126/a- 
hANP and urodilatin (CDD/ANP-95-126) by a 
membrane preparation from the kidney cortex. 
For proteolysis (37°C) CDD/ANP was dissolved in 
phosphate-buffered saline (PBS: 0.05 M phosphate, 0.1 M 
NaCI, pH 7.4) at a final concentration of 100 pg/ml. The reac- 
tion was started by addition of membranes (8O~g/lOO pg 
CDD/ANP) and terminated by addition of 0.1 ml of 0.1% tri- 
fluoroacetic acid (TFA) to 0.05 ml reaction volume. This was 
followed by centrifugation for 1 min in an Eppendorf cen- 
trifuge 3200 at maximum speed and rapid freezing with liquid 
Nz. The samples were separated by high-performance liquid 
chromatography (HPLC) on a reverse-phase column (Aqua- 
pore RP-300, 4.6 x 100 mm, Applied Biosystems). The column 
was developed by a linear gradient of acetonitrile (lo-70%) 
containing 0.1% TFA using a device from Applied Biosystems. 
Absorption was determined at 220 nm. Fractions were collected 
manually. 
Bioassays were carried out as in [16] using rabbit aorta strips 
in an organ bath. 
Sequence analysis was performed on a gas-phase sequencer 
model 477A from Applied Biosystems. Phenylthiohydantoin 
derivates were separated by reverse-phase HPLC according to 
1311. 
3. RESULTS AND DISCUSSION 
2. MATERIALS AND METHODS 
Synthetic CDD-99-126/a-hANP and urodilatin (CDD/ 
ANP-95-126) were obtained from Bissendorf Biochemicals 
(Hannover, FRG). All other reagents used were of analytical 
grade, Reagents for amino acid sequence analysis were ultra 
pure and purchased from Applied Biosystems. Preparation of 
membranes from kidney cortex followed basically the pro- 
cedure originally described [21]. Membrane preparation was 
carried out at 0-4°C on ice. Kidneys were obtained from dogs 
and stored at - 20°C until use. The cortex was dissected, minc- 
ed and resuspended in 3 ml homogenization buffer [lo mM 
sodium phosphate (pH 7.4), 1 mM MgClz, 30 mM NaCl, 
0.01% NaNS and 10 pg/l DNase]. Homogenization was carried 
out by use of an Ultra-Turrax (3 x 3-s bursts with 2-min inter- 
vals). The homogenate was centrifuged twice for 10 min at 
500 x g and layered (6 ml) onto 5 ml sucrose (41%, w/v). 
Following centrifugation at 100000 x g for 30 min the mem- 
branes were collected from the buffer/sucrose interfase and 
washed twice with 10 mM Tris (pH 7.4). Storage was with the 
same buffer at - 70°C. Protein determination was done by the 
method of Lowry et al. [30] using bovine serum albumin as a 
standard. 
CDD-99- 126/a-hANP (25 pg) was incubated 
with 20 pg kidney cortex membranes from dog. At 
various time intervals aliquots were removed from 
the reaction volume: immediately after the start of 
the enzymatic reaction (0 min), after 5, 10, 40 and 
90 min of incubation. A typical experiment is 
demonstrated in fig. 1A showing consecutive 
HPLC profiles of CDD/ANP-99- 126 proteolysis. 
At time zero CDD/ANP-99-126 is eluted as a 
single peak with 38% acetonitrile. During incuba- 
tion with the kidney membrane preparation the 
content of CDD/ANP-99-126 decreased at the 
cost of a minor peak (indicated by an asterisk in 
fig. 1A) eluting with 36% acetonitrile. The conver- 
sion of substrate into product is summarized as a 
function of time in fig.2. After 90 min incubation 
the reaction reached the maximum level where all 
CDD/ANP-99-126 had been degraded completely. 
Only the product eluting at 36% acetonitrile was 
visible. 
Biotests using rabbit aorta strips ensured that 
only the major peak (eluting at 38% acetonitrile) 
June 1988 
Fig.1. Reverse-phase HPLC profiles of time-dependent (0, 5, 10, 40 and 90 min incubation) CDD/ANP-99-126 degradation by dog 
kidney cortex membranes (A) and heat-treated (5 and 90 min incubation) membrane preparations (B) and incubation of 
CDD/ANP-95-126 (urodilatin) with kidney cortex membranes (0, 5, 40 and 90 min). At various time intervals aliquots (5 pg 
CDDIANP) were removed and separated by HPLC. Absorbance of the column effluent was measured at 220 nm (-). The column 
was developped by increasing the concentration of acetonitrile (- --). The bioactive form of CDD/ANP-99-126 and 
CDD/ANP-95-126 elutes at 38% acetonitrile, while the degraded product appears with 36% acetonitrile. The cleaved product is in- 
dicated by the asterisk. 
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Fig.2. Rate of degradation of CDDIANP-99-126 (0) and 
CDD/ANP-95-126 (urodilatin) (*) during incubation with 
kidney membranes and appearance of its proteolytic products 
(0,o). The maximal absorbance of the peaks of the reverse- 
phase HPLC column at the appropriate time intervals was plot- 
ted vs time (cf. fig.1). 
represents the bioactive form and corresponds to 
CDD/ANP-99-126. A typical experiment for 
analysis of bioactivity is given in fig.3. For the test 
the two peaks (eluting at 38 and 36% acetonitrile) 
were collected manually from HPLC runs. Both 
fractions were lyophilized and after resolubiliza- 
tion in organ bath solution directly applied to the 
precontracted aorta muscle preparation. The peak 
generated during incubation with the membrane 
preparation eluting at 36% acetonitrile exhibited 
no vasorelaxant potency indicating proteolytic 
processing as described by others [20,21]. 
The structure of the cleaved product was anal- 
ysed by revealing t’he amino acid sequence. 
CDD/ANP-99-126 was incubated with kidney 
membranes for 90 min and the peak eluting at 
36% acetonitrile was collected. Incubation for 
90 min ensures complete degradation of the bioac- 
tive peak eluting at 38% acetonitrile which cor- 
responds to intact CDD/ANP-99-126. Therefore, 
only the product of the enzymatic degradation was 
used for the sequence studies. The peptide was sub- 
mitted to 17 cycles of amino-terminal sequence 
a 
1 
I 
0 20 40 50 60 70 80 90 
time IminI 
Fig.3. Effect of degraded CDD/ANP-99-126 after separation 
by reverse-phase HPLC (36% acetonitrile) of 10 min incuba- 
tion with kidney cortex membranes on rabbit aorta. For control 
intact CDD/ANP-99-126 (eluted with 38% acetonitrile) from 
the same column run was used. The aorta was precontracted 
with lo-’ M norepinephrine. Upon a plateau force level being 
achieved the proteolytically cleaved CDD/ANP-99-126 (5 ~1) 
was added, (1) followed by incubation with 2 pl of the bioactive 
peptide (2). The ratio of proteolytically degraded 
CDD/ANP-99-126 to intact peptide was 1:2.5 as estimated 
from the corresponding absorbance maxima (cf. also fig.lA, 
10 min incubation). At position a (40 min incubation) the 
recorder speed was increased. 
analysis. In the first cycle two distinct amino- 
terminal residues (serine and phenylalanine) were 
identified. Further sequence analysis revealed that 
the peak was similar to CDD/ANP-99-126 except 
that it contained a single cleavage between the 
Cys-105 and Phe-106 bond. Cys was not deter- 
mined by the sequence analysis but assigned from 
the known sequence. Therefore, in our experiment 
using CDD/ANP-99-126 as a substrate proteolysis 
by the membrane preparation from dog kidney 
caused a single cleavage within the disulfide loop 
between the residues in position Cys-105 and 
Phe-106. Thus, the enzymatic processing that inac- 
tivates CDD/ANP-99-126 is similar to that 
demonstrated with membrane preparations from 
rabbit [20] and rat kidneys [21]. 
As a control the cortex membrane preparation 
was inactivated by boiling (15 min) prior to in- 
cubation with CDD/ANP-99-126. The experiment 
is shown in fig.lB. Heat treatment of the mem- 
brane preparation completely destroys the proteo- 
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lytic activity. CDD/ANP-99-126 is not degraded 
during incubation for at least 90 min. 
Urodilatin (CDD/ANP-95-126) which belongs 
to the CDD family was submitted to the same ex- 
perimental procedure as described above for 
CDD/ANP-99-126. The experiment is shown in 
fig.lC. Urodilatin was incubated with the kidney 
cortex membrane preparation by using the same 
incubation procedure and concentrations. After 0, 
5, 40 and 90 min aliquots were removed from the 
test tube and separated by HPLC. In contrast to 
CDD/ANP-99-126 urodilatin (CDD/ANP-95- 
126) was not proteolytically degraded within 5 min 
incubation. Only minor proteolysis was observed 
within 40 min incubation without further increase 
in product. Note that under similar conditions 
CDD/ANP-99-126 was completely destroyed 
(fig.lA). As depicted in fig.2 the total amount of 
urodilatin (CDD/ANP-95-126) decreases during 
prolonged incubation as can also be seen with 
CDD/ANP-99-126. This is not surprising because 
a crude membrane preparation was used. There- 
fore, one has to expect a variety of proteolytic ac- 
tivities [20,21,32]. However, the decrease of 
urodilatin is much slower. Treatment of a sample 
containing CDD/ANP-99-126 with the cortex 
membrane preparation thus enables rapid detec- 
tion of the according peptide by appropriate 
alteration of the elution profile. 
The proteolytic enzyme in rat kidney cortex 
membrane preparations responsible for CDD/ 
ANP-99-126 degradation has been characterized 
as a metalloendoprotease 12 11. The enzyme cleaves 
atria1 natriuretic peptide (CDD/ANP-99-126) at a 
single cleavage site between Cys-105 and Phe-106. 
A similar proteolytic enzyme preparation was 
prepared from rabbit kidney membranes [20]. This 
preparation degraded CDD/ANP-99-126 as well 
as a shorter form of CDD/ANP-103-126 (atrio- 
peptin III) indicating that the presence of the te- 
trapeptide Ser-99-Leu-lOO-Arg-lOl-Arg-102 at 
the amino terminus does not protect against diges- 
tion by the proteolytic activity in the membrane 
preparation [20]. It was reported that CDD/ANP- 
103-126 was not cleaved exclusively between the 
Cys-Phe bond. At least 3 cleavage sites have been 
reported [20]. This observation was confirmed as 
Koehn et al. [21] also report appearance of mul- 
tiple products by use of shorter peptides. Our 
results, however, achieved by the use of a more ex- 
tended peptide (CDD/ANP-95-126), demonstrate 
that the proteolytic enzyme in dog kidney mem- 
brane preparations which cleaves CDD/ANP-99- 
126 at the ring structure is inactive against uro- 
dilatin (CDD/ANP-95-126). Therefore, the tetra- 
peptide Thr-95-Ala-96-Pro-97-Arg, 98 prevents 
proteolytic attack and metabolization by the 
kidney while CDD/ANP-99-126 undergoes hydro- 
lysis and inactivation. The present data demon- 
strate for the first time a degradation-resistent 
peptide that belongs to the CDD/ANP family. 
From the fact that urodilatin (CDD/ANP-95-126) 
is excreted by the kidney [27] and since the kidney 
may be considered as the target tissue for the pep- 
tide action, it appears logical that the secreted pep- 
tide needs a design which prevents biological 
inactivation. 
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